Economic benefits and costs associated with target vaccinations

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

BACKGROUND: As a therapeutic class, vaccines are generally considered to be the health care intervention that provides the best value. In the pharmacoeconomic study of vaccines, it is common for researchers to conduct their analyses from a societal perspective, including direct medical costs as well as indirect costs. OBJECTIVE: To discuss the data elements of pharmacoeconomic analyses of vaccines and review recently published analyses of emerging vaccines. SUMMARY: Myriad pharmacoeconomic analyses of vaccines currently in use have been conducted with varying results. A number of products, such as the diphtheria-tetanus-acellular pertussis, hepatitis B, and varicella vaccines, have been shown to be cost-effective from a societal perspective. Yet, other products, such as the pneumococcal conjugate vaccine, have demonstrated less benefit than the cost of their respective vaccination programs. In general, these analyses can be used as a starting point to frame the benefits of specific vaccines in managed care with a balanced view of the necessary societal perspectives. To date, 6 pharmacoeconomic models have evaluated vaccination against human papillomavirus, with all demonstrating some cost benefit when the vaccine was used in female patients who fell within the indicated age range. CONCLUSIONS: In general, as a therapeutic class, vaccines are extremely cost-effective agents. In addition, they are one of the few public health interventions that may directly lower medical costs. In conducting pharmacoeconomic analyses for agents in this class, researchers must consider costs incurred at both the health system and societal levels, as well as cost savings realized through the prevention of disease. Copyright

Original languageEnglish (US)
JournalJournal of managed care pharmacy : JMCP.
Volume13
Issue number7 SUPPL.
StatePublished - Sep 2007

Fingerprint

Cost-Benefit Analysis
Vaccination
Pharmaceutical Economics
Vaccines
Economics
Costs and Cost Analysis
Costs
Research Personnel
Chickenpox Vaccine
Conjugate Vaccines
Hepatitis B Vaccines
Pneumococcal Vaccines
Diphtheria
Cost Savings
Whooping Cough
Tetanus
Managed Care Programs
Public health
Health care
Public Health

Keywords

  • Cost
  • Cost-effective
  • Hepatitis
  • HPV
  • Pharmacoeconomic
  • Vaccine

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Health Policy
  • Pharmacy

Cite this

Economic benefits and costs associated with target vaccinations. / Armstrong, Edward P.

In: Journal of managed care pharmacy : JMCP., Vol. 13, No. 7 SUPPL., 09.2007.

Research output: Contribution to journalArticle

@article{555fed5cc8fc4727b8fa257a792e2ac8,
title = "Economic benefits and costs associated with target vaccinations",
abstract = "BACKGROUND: As a therapeutic class, vaccines are generally considered to be the health care intervention that provides the best value. In the pharmacoeconomic study of vaccines, it is common for researchers to conduct their analyses from a societal perspective, including direct medical costs as well as indirect costs. OBJECTIVE: To discuss the data elements of pharmacoeconomic analyses of vaccines and review recently published analyses of emerging vaccines. SUMMARY: Myriad pharmacoeconomic analyses of vaccines currently in use have been conducted with varying results. A number of products, such as the diphtheria-tetanus-acellular pertussis, hepatitis B, and varicella vaccines, have been shown to be cost-effective from a societal perspective. Yet, other products, such as the pneumococcal conjugate vaccine, have demonstrated less benefit than the cost of their respective vaccination programs. In general, these analyses can be used as a starting point to frame the benefits of specific vaccines in managed care with a balanced view of the necessary societal perspectives. To date, 6 pharmacoeconomic models have evaluated vaccination against human papillomavirus, with all demonstrating some cost benefit when the vaccine was used in female patients who fell within the indicated age range. CONCLUSIONS: In general, as a therapeutic class, vaccines are extremely cost-effective agents. In addition, they are one of the few public health interventions that may directly lower medical costs. In conducting pharmacoeconomic analyses for agents in this class, researchers must consider costs incurred at both the health system and societal levels, as well as cost savings realized through the prevention of disease. Copyright",
keywords = "Cost, Cost-effective, Hepatitis, HPV, Pharmacoeconomic, Vaccine",
author = "Armstrong, {Edward P}",
year = "2007",
month = "9",
language = "English (US)",
volume = "13",
journal = "Journal of managed care & specialty pharmacy",
issn = "2376-0540",
publisher = "Academy of Managed Care Pharmacy (AMCP)",
number = "7 SUPPL.",

}

TY - JOUR

T1 - Economic benefits and costs associated with target vaccinations

AU - Armstrong, Edward P

PY - 2007/9

Y1 - 2007/9

N2 - BACKGROUND: As a therapeutic class, vaccines are generally considered to be the health care intervention that provides the best value. In the pharmacoeconomic study of vaccines, it is common for researchers to conduct their analyses from a societal perspective, including direct medical costs as well as indirect costs. OBJECTIVE: To discuss the data elements of pharmacoeconomic analyses of vaccines and review recently published analyses of emerging vaccines. SUMMARY: Myriad pharmacoeconomic analyses of vaccines currently in use have been conducted with varying results. A number of products, such as the diphtheria-tetanus-acellular pertussis, hepatitis B, and varicella vaccines, have been shown to be cost-effective from a societal perspective. Yet, other products, such as the pneumococcal conjugate vaccine, have demonstrated less benefit than the cost of their respective vaccination programs. In general, these analyses can be used as a starting point to frame the benefits of specific vaccines in managed care with a balanced view of the necessary societal perspectives. To date, 6 pharmacoeconomic models have evaluated vaccination against human papillomavirus, with all demonstrating some cost benefit when the vaccine was used in female patients who fell within the indicated age range. CONCLUSIONS: In general, as a therapeutic class, vaccines are extremely cost-effective agents. In addition, they are one of the few public health interventions that may directly lower medical costs. In conducting pharmacoeconomic analyses for agents in this class, researchers must consider costs incurred at both the health system and societal levels, as well as cost savings realized through the prevention of disease. Copyright

AB - BACKGROUND: As a therapeutic class, vaccines are generally considered to be the health care intervention that provides the best value. In the pharmacoeconomic study of vaccines, it is common for researchers to conduct their analyses from a societal perspective, including direct medical costs as well as indirect costs. OBJECTIVE: To discuss the data elements of pharmacoeconomic analyses of vaccines and review recently published analyses of emerging vaccines. SUMMARY: Myriad pharmacoeconomic analyses of vaccines currently in use have been conducted with varying results. A number of products, such as the diphtheria-tetanus-acellular pertussis, hepatitis B, and varicella vaccines, have been shown to be cost-effective from a societal perspective. Yet, other products, such as the pneumococcal conjugate vaccine, have demonstrated less benefit than the cost of their respective vaccination programs. In general, these analyses can be used as a starting point to frame the benefits of specific vaccines in managed care with a balanced view of the necessary societal perspectives. To date, 6 pharmacoeconomic models have evaluated vaccination against human papillomavirus, with all demonstrating some cost benefit when the vaccine was used in female patients who fell within the indicated age range. CONCLUSIONS: In general, as a therapeutic class, vaccines are extremely cost-effective agents. In addition, they are one of the few public health interventions that may directly lower medical costs. In conducting pharmacoeconomic analyses for agents in this class, researchers must consider costs incurred at both the health system and societal levels, as well as cost savings realized through the prevention of disease. Copyright

KW - Cost

KW - Cost-effective

KW - Hepatitis

KW - HPV

KW - Pharmacoeconomic

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=35349015305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35349015305&partnerID=8YFLogxK

M3 - Article

C2 - 17955624

AN - SCOPUS:35349015305

VL - 13

JO - Journal of managed care & specialty pharmacy

JF - Journal of managed care & specialty pharmacy

SN - 2376-0540

IS - 7 SUPPL.

ER -